In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter aortic valve implantation (TAVI) was associated with a lower 5-year ...

On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. Start Your Mornings Smarter! Wake up with Breakfast ...

The US Food and Drug Administration has expanded its indications for the Evolut family of valves (Medtronic) to include redo TAVI inpatients at high risk for surgery. The approval now includes use for ...

Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...

A minimalist approach to transcatheter aortic valve implantation (TAVI), without sedation, was noninferior to the standard approach for the primary outcome at 30 days, according to late-breaking ...

Medtronic plc received U.S. FDA approval for the expanded redo TAVR indication of the Evolut transcatheter aortic valve replacement system. The approval allows for valve-in-valve implantation of a new ...

The company's TAVR system did well when put through its paces. It was tested on patients with a severe heart valve disorder. On Sunday, Medtronic published five-year data from a low-risk clinical ...